Literature DB >> 18793785

Central roles for IL-2 and MCP-1 following intranasal exposure to SEB: a new mouse model.

Louis M Huzella1, Marilyn J Buckley, Derron A Alves, Bradley G Stiles, Teresa Krakauer.   

Abstract

Murine models for bacterial superantigens like staphylococcal enterotoxin B (SEB) have to date been rather cumbersome. The reasons include: (1) necessary use of potentiating agents such as actinomycin D, d-galactosamine, lipopolysaccharide (LPS), or viruses; (2) high toxin amounts required to elicit effects; and/or (3) generation of phenotypic-stable transgenic animals. Our study employed readily available C3H/HeJ (TLR4 negative, LPS-nonresponsive) mice with intranasal and intraperitoneal administration of low microgram quantities of SEB. These animals responded to SEB with severe lung inflammation and hypothermia, culminating in death. A survey of cytokines/chemokines in sera and lungs after lethal intoxication revealed that monocyte chemoattractant protein-1 and interleukin-2 were associated with effects in this model. In contrast, SEB had minimal effects upon congenic (TLR4 positive, LPS-responsive) C3H/OuJ mice. Lethality of SEB in C3H/HeJ mice was neutralized with SEB-specific antibodies, suggesting potential utility of this model for future therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793785     DOI: 10.1016/j.rvsc.2008.07.020

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  22 in total

1.  Role of miRNA in the regulation of inflammatory genes in staphylococcal enterotoxin B-induced acute inflammatory lung injury and mortality.

Authors:  Roshni Rao; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Toxicol Sci       Date:  2015-01-05       Impact factor: 4.849

2.  Determining the immunological characteristics of a novel human monoclonal antibody developed against staphylococcal enterotoxin B.

Authors:  Yuanyuan Liu; Zhen Song; Shuang Ge; Jinyong Zhang; Limin Xu; Feng Yang; Dongshui Lu; Ping Luo; Jiang Gu; Quanming Zou; Hao Zeng
Journal:  Hum Vaccin Immunother       Date:  2020-04-10       Impact factor: 3.452

3.  Bacterial Toxins-Staphylococcal Enterotoxin B.

Authors:  Bettina C Fries; Avanish K Varshney
Journal:  Microbiol Spectr       Date:  2013-12

Review 4.  Antibodies for biodefense.

Authors:  Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

5.  CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury.

Authors:  Sadiye Amcaoglu Rieder; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

6.  Δ(9) Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells.

Authors:  R Rao; P S Nagarkatti; M Nagarkatti
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

7.  Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo.

Authors:  Teresa Krakauer; Marilyn Buckley; Haleem J Issaq; Stephen D Fox
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 8.  Therapeutic down-modulators of staphylococcal superantigen-induced inflammation and toxic shock.

Authors:  Teresa Krakauer
Journal:  Toxins (Basel)       Date:  2010-07-29       Impact factor: 4.546

9.  Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock.

Authors:  Teresa Krakauer; Marilyn Buckley
Journal:  Toxins (Basel)       Date:  2012-09-18       Impact factor: 4.546

Review 10.  PI3K/Akt/mTOR, a pathway less recognized for staphylococcal superantigen-induced toxicity.

Authors:  Teresa Krakauer
Journal:  Toxins (Basel)       Date:  2012-11-15       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.